In MRSA bacteremia, adding a β-lactam to usual care did not improve a composite outcome at 90 days.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32539506.
- Also identified by DOI 10.7326/ACPJ202006160-067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tong SY, Lye DC, Yahav D, et al. <b>Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial.</b> JAMA. 2020;323:527-37. 32044943.
Medical subject headings
- Bacteremia
- Daptomycin
- Methicillin-Resistant Staphylococcus aureus
- Staphylococcal Infections